Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 2

Comparison of platelet count and mean platelet volume values before and after treatment in rheumatoid arthritis and ankylosing spondylitis patients receiving tumor necrosis factor alpha inhibitor therapy

Pages
434–437
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Likewise, there was a decrease in CRP value but it was not statistically significant.Conclusion: In this study, it was concluded that the MPV value and platelet count could be inexpensive biomarkers in the follow-up of RA and AS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In our study, we planned to reveal the change of the mean platelet volume (MPV) with anti-TNF treatment given in patients with Rheumatoid-Arthritis (RA) and Ankylosing-Spondylitis (AS) and to evaluate the clinical importance of MPV in the follow-up of these diseases.Materials and Methods: Patients who applied to our hospital's between 2011 and 2013 were included in the study. 40 patients participated in the study.
📊
Key Findings & Data:The average ages of the patients were 43.8±9.9 years (range:25-68 years).
💡
Conclusion & Impact:Likewise, there was a decrease in CRP value but it was not statistically significant.Conclusion: In this study, it was concluded that the MPV value and platelet count could be inexpensive biomarkers in the follow-up of RA and AS.
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: In our study, we planned to reveal the change of the mean platelet volume (MPV) with anti-TNF treatment given in patients with Rheumatoid-Arthritis (RA) and Ankylosing-Spondylitis (AS) and to evaluate the clinical importance of MPV in the follow-up of these diseases.Materials and Methods: Patients who applied to our hospital's between 2011 and 2013 were included in the study. 40 patients participated in the study. The average ages of the patients were 43.8±9.9 years (range:25-68 years). All patients were examined retrospectively, Hemoglobin (Hb), Hematocrit (Hct), Platelet count, Mean Red-Blood-Cell Volume (MCV), MPV, Erythrocyte-Sedimentation-Rate (ESR), C-Reactive Protein (CRP) before anti-TNF treatment were recorded. Then, the same values were checked six months after the treatment. Averages of the Hb, Hct, MCV, PLT, MPV, CRP, ESH parameters of patients before and after treatment were compared with each other.Results: When the values before and after the treatment were compared, there was a significant decrease in ESR (p:0.002). There was also a statistically significant increase in Hb and Hct values after treatment (p:0.002, p:0.039, respectively). A significant decrease was observed in mean platelet count and MPV values after treatment (p:0.001). Although there was an increase in the MCV value, it was not statistically significant. Likewise, there was a decrease in CRP value but it was not statistically significant.Conclusion: In this study, it was concluded that the MPV value and platelet count could be inexpensive biomarkers in the follow-up of RA and AS. However, more controlled prospective studies are needed in this regard.

🔖

Cite This Article

KONUR, Ş., DEMİRTUNÇ, R. (2022). Comparison of platelet count and mean platelet volume values before and after treatment in rheumatoid arthritis and ankylosing spondylitis patients receiving tumor necrosis factor alpha inhibitor therapy. Annals of Medical Research, Cilt: 28 - Sayı: 2, 434–437. https://ajindex.com/articles/446359

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Myasoedova E, Davis J, Matteson EL, et al. Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985-2014. Ann Rheum Dis 2020;2019:216694
  2. Zhao J, Huang C, Huang H, et al. Prevalence of ankylosing spondylitis in a Chinese population: a systematic review and meta-analysis. Rheumatol Int 2020;20:35-47
  3. Otón T, Carmona L. The epidemiology of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2020;24:101477
  4. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229- 34
  5. Heijde D. Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebocontrolled trial (ASSERT). Arthritis Rheum 2005;52:582-91
  6. Mei YJ, Mao YM, Cao F, et al. Using internet search data to explore the global public concerns in ankylosing spondylitis. Postgrad Med J 2020;24:16-22 7. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75
  7. Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: costeffectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 2009;36:1421-8
  8. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res 2002;4:307-21
  9. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70
  10. Keller C, Davis J. Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis. 2003;62:1128–32
  11. Yazici Y, Xie L, Ogbomo A, et al. Analysis of realworld treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab. Biologics. 2018;12:127-34
  12. Francois RJ, Neure L, Sieper J, et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two pat